Proton-pump inhibitor

Serious Concerns About Frequent Heartburn Medications Spurs Demand for Healthy Alternatives

Retrieved on: 
Thursday, October 26, 2023

VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica, a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief. This move comes in response to the recent revelation of a study linking long-term usage of Proton Pump Inhibitors (PPIs) to potential health risks, including dementia. With a commitment to providing safe and effective solutions, Enzymedica offers consumers a variety of options that not only relieve symptoms of occasional heartburn resulting from food and diet choices, but also promote overall digestive wellness.

Key Points: 
  • VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica , a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief.
  • The heartburn solutions category has faced stagnation due to a lack of innovation, concerns about drug side effects and confusion surrounding the frequent, long-term usage of PPIs and other acid inhibitors.
  • The recent study shedding light on potential health risks associated with PPIs has left consumers seeking trustworthy alternatives that prioritize their well-being.
  • These products offer consumers a reliable and convenient way to address their occasional heartburn concerns with natural, science-backed solutions.

Global Digestive Remedies Market 2023: Sector is Expected to Reach $22.53 Billion by 2028 at a CAGR of 3.3% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 1, 2023

By Formulation: Based on the formulation, the global digestive remedies market can be segmented into four segments: Capsules, Tablets, Powder, and Others.

Key Points: 
  • By Formulation: Based on the formulation, the global digestive remedies market can be segmented into four segments: Capsules, Tablets, Powder, and Others.
  • By Distribution Channel: The global digestive remedies market can be divided into three segments based on distribution channel: Pharmacies & Drugstores, Online Providers, and Others.
  • By End User: The global digestive remedies market can be divided into two segments according to end user: Adult, and Pediatric.
  • In 2022, North America dominated the global digestive remedies market due to the high prevalence of digestive disorders.

Global Gastrointestinal Therapeutics Market Report 2022: Rising Expenditure on Healthcare Boosts Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023

The Global Gastrointestinal Therapeutics Market size is expected to reach $45.9 billion by 2028, rising at a market growth of 3.8% CAGR during the forecast period.

Key Points: 
  • The Global Gastrointestinal Therapeutics Market size is expected to reach $45.9 billion by 2028, rising at a market growth of 3.8% CAGR during the forecast period.
  • More developing countries would have greater access to high-quality healthcare due to the fast economic development and growing healthcare cost.
  • The rising incidence of gastrointestinal diseases, which ranges from severe to moderate, like ulcerative colitis, Crohn's disease, and other gastrointestinal diseases, is surging the requirement for advanced therapeutics.
  • On the basis of route of administration, the gastrointestinal therapeutics market is divided into oral, injectable and others.

Implantica Applauded by Frost & Sullivan for Transforming Gastroesophageal Reflux Disease Treatment with Its Revolutionary Implant RefluxStop™

Retrieved on: 
Thursday, June 16, 2022

SAN ANTONIO, June 16, 2022 /PRNewswire/ --– Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device. The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment. The device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of commonly used drug treatment, Proton Pump Inhibitors (PPIs) and current surgical methods for treating acid reflux disease. The RefluxStop device is placed outside of the top part of the stomach (fundus wall) during laparoscopic surgery, reconstructing the angle of His, an acute angle at the esophagogastric junction. Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.

Key Points: 
  • SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device.
  • The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment.
  • Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.
  • Click here to view the full multimedia release: https://best-practices.frost.com/implantica/
    According to a recently published global study in Nature medical journal, there are more than 1 Billion people suffering from reflux disease.

Implantica Applauded by Frost & Sullivan for Transforming Gastroesophageal Reflux Disease Treatment with Its Revolutionary Implant RefluxStop™

Retrieved on: 
Thursday, June 16, 2022

SAN ANTONIO, June 16, 2022 /PRNewswire/ --– Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device. The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment. The device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of commonly used drug treatment, Proton Pump Inhibitors (PPIs) and current surgical methods for treating acid reflux disease. The RefluxStop device is placed outside of the top part of the stomach (fundus wall) during laparoscopic surgery, reconstructing the angle of His, an acute angle at the esophagogastric junction. Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.

Key Points: 
  • SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device.
  • The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment.
  • Such reconstruction and the RefluxStop device restores and maintains the normal physiological situation and prevents the reflux of the stomach content into the esophagus.
  • Click here to view the full multimedia release: https://best-practices.frost.com/implantica/
    According to a recently published global study in Nature medical journal, there are more than 1 Billion people suffering from reflux disease.

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.